ZEALAND PHARMA A/S (22Z.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:22Z - DK0060257814 - Common Stock
67.88 EUR
+0.58 (+0.86%)
We assign a fundamental rating of 6 out of 10 to 22Z. 22Z was compared to 83 industry peers in the Biotechnology industry. 22Z is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 22Z is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make 22Z suitable for growth investing!
1. Profitability
1.1 Basic Checks
22Z had positive earnings in the past year.
22Z had a positive operating cash flow in the past year.
In the past 5 years 22Z always reported negative net income.
22Z had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
22Z has a better Return On Assets (38.95%) than 97.59% of its industry peers.
With an excellent Return On Equity value of 43.15%, 22Z belongs to the best of the industry, outperforming 96.39% of the companies in the same industry.
22Z has a Return On Invested Capital of 32.76%. This is amongst the best in the industry. 22Z outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.95% | ||
| ROE | 43.15% | ||
| ROIC | 32.76% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 22Z (71.47%) is better than 97.59% of its industry peers.
With an excellent Operating Margin value of 79.38%, 22Z belongs to the best of the industry, outperforming 97.59% of the companies in the same industry.
22Z has a better Gross Margin (99.99%) than 97.59% of its industry peers.
In the last couple of years the Gross Margin of 22Z has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 79.38% | ||
| PM (TTM) | 71.47% | ||
| GM | 99.99% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 22Z is creating value.
Compared to 1 year ago, 22Z has more shares outstanding
22Z has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 22Z has been reduced compared to a year ago.
2.2 Solvency
22Z has an Altman-Z score of 11.69. This indicates that 22Z is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 11.69, 22Z belongs to the best of the industry, outperforming 89.16% of the companies in the same industry.
The Debt to FCF ratio of 22Z is 0.06, which is an excellent value as it means it would take 22Z, only 0.06 years of fcf income to pay off all of its debts.
22Z's Debt to FCF ratio of 0.06 is amongst the best of the industry. 22Z outperforms 97.59% of its industry peers.
22Z has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
22Z's Debt to Equity ratio of 0.03 is fine compared to the rest of the industry. 22Z outperforms 71.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.06 | ||
| Altman-Z | 11.69 |
ROIC/WACC4.72
WACC6.94%
2.3 Liquidity
22Z has a Current Ratio of 14.10. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 22Z (14.10) is better than 95.18% of its industry peers.
22Z has a Quick Ratio of 14.10. This indicates that 22Z is financially healthy and has no problem in meeting its short term obligations.
22Z has a Quick ratio of 14.10. This is amongst the best in the industry. 22Z outperforms 95.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 14.1 | ||
| Quick Ratio | 14.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 661.53% over the past year.
Looking at the last year, 22Z shows a very strong growth in Revenue. The Revenue has grown by 11809.72%.
The Revenue has been growing by 8.69% on average over the past years. This is quite good.
EPS 1Y (TTM)661.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.52%
Revenue 1Y (TTM)11809.72%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%1022.74%
3.2 Future
The Earnings Per Share is expected to grow by 0.04% on average over the next years.
Based on estimates for the next years, 22Z will show a very strong growth in Revenue. The Revenue will grow by 122.10% on average per year.
EPS Next Y667.27%
EPS Next 2Y77.52%
EPS Next 3Y11.31%
EPS Next 5Y0.04%
Revenue Next Year11480.1%
Revenue Next 2Y691.79%
Revenue Next 3Y250.33%
Revenue Next 5Y122.1%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.45, the valuation of 22Z can be described as very cheap.
Based on the Price/Earnings ratio, 22Z is valued cheaply inside the industry as 96.39% of the companies are valued more expensively.
22Z is valuated cheaply when we compare the Price/Earnings ratio to 26.49, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 27.06 indicates a quite expensive valuation of 22Z.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 22Z indicates a rather cheap valuation: 22Z is cheaper than 80.72% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of 22Z to the average of the S&P500 Index (23.69), we can say 22Z is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.45 | ||
| Fwd PE | 27.06 |
4.2 Price Multiples
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 22Z indicates a rather cheap valuation: 22Z is cheaper than 97.59% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.17 | ||
| EV/EBITDA | -0.35 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y77.52%
EPS Next 3Y11.31%
5. Dividend
5.1 Amount
No dividends for 22Z!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:22Z (12/5/2025, 7:00:00 PM)
67.88
+0.58 (+0.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners49.36%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap3.13B
Revenue(TTM)9.16B
Net Income(TTM)6.54B
Analysts82.4
Price Target101.93 (50.16%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.92%
Min EPS beat(2)-5.54%
Max EPS beat(2)31.39%
EPS beat(4)2
Avg EPS beat(4)-143.51%
Min EPS beat(4)-623.11%
Max EPS beat(4)31.39%
EPS beat(8)3
Avg EPS beat(8)-73.88%
EPS beat(12)5
Avg EPS beat(12)-38.79%
EPS beat(16)7
Avg EPS beat(16)-27.86%
Revenue beat(2)1
Avg Revenue beat(2)21.02%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)45.58%
Revenue beat(4)1
Avg Revenue beat(4)-24.03%
Min Revenue beat(4)-74.61%
Max Revenue beat(4)45.58%
Revenue beat(8)4
Avg Revenue beat(8)20.68%
Revenue beat(12)7
Avg Revenue beat(12)58.52%
Revenue beat(16)7
Avg Revenue beat(16)31.76%
PT rev (1m)-5.42%
PT rev (3m)N/A
EPS NQ rev (1m)-36.65%
EPS NQ rev (3m)N/A
EPS NY rev (1m)2.65%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-21.2%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.15%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.45 | ||
| Fwd PE | 27.06 | ||
| P/S | 2.55 | ||
| P/FCF | 3.17 | ||
| P/OCF | 3.16 | ||
| P/B | 1.54 | ||
| P/tB | 1.54 | ||
| EV/EBITDA | -0.35 |
EPS(TTM)12.45
EY18.34%
EPS(NY)2.51
Fwd EY3.69%
FCF(TTM)21.4
FCFY31.53%
OCF(TTM)21.47
OCFY31.62%
SpS26.58
BVpS44.02
TBVpS43.98
PEG (NY)0.01
PEG (5Y)N/A
Graham Number111.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 38.95% | ||
| ROE | 43.15% | ||
| ROCE | 46.53% | ||
| ROIC | 32.76% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 79.38% | ||
| PM (TTM) | 71.47% | ||
| GM | 99.99% | ||
| FCFM | 80.53% |
ROA(3y)-41.65%
ROA(5y)-44.45%
ROE(3y)-68.01%
ROE(5y)-76.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5Y-2.45%
F-Score8
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | 0.06 | ||
| Debt/EBITDA | 0.05 | ||
| Cap/Depr | 86.21% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | 432.5 | ||
| Cash Conversion | 101.39% | ||
| Profit Quality | 112.67% | ||
| Current Ratio | 14.1 | ||
| Quick Ratio | 14.1 | ||
| Altman-Z | 11.69 |
F-Score8
WACC6.94%
ROIC/WACC4.72
Cap/Depr(3y)51.82%
Cap/Depr(5y)53.82%
Cap/Sales(3y)13.05%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)661.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.52%
EPS Next Y667.27%
EPS Next 2Y77.52%
EPS Next 3Y11.31%
EPS Next 5Y0.04%
Revenue 1Y (TTM)11809.72%
Revenue growth 3Y-16.72%
Revenue growth 5Y8.69%
Sales Q2Q%1022.74%
Revenue Next Year11480.1%
Revenue Next 2Y691.79%
Revenue Next 3Y250.33%
Revenue Next 5Y122.1%
EBIT growth 1Y751.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year736.81%
EBIT Next 3Y-7.93%
EBIT Next 5Y17.81%
FCF growth 1Y1048.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1076.19%
OCF growth 3YN/A
OCF growth 5YN/A
ZEALAND PHARMA A/S / 22Z.DE FAQ
What is the ChartMill fundamental rating of ZEALAND PHARMA A/S (22Z.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE.
What is the valuation status of ZEALAND PHARMA A/S (22Z.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to ZEALAND PHARMA A/S (22Z.DE). This can be considered as Fairly Valued.
What is the profitability of 22Z stock?
ZEALAND PHARMA A/S (22Z.DE) has a profitability rating of 5 / 10.
What is the valuation of ZEALAND PHARMA A/S based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ZEALAND PHARMA A/S (22Z.DE) is 5.45 and the Price/Book (PB) ratio is 1.54.
What is the financial health of ZEALAND PHARMA A/S (22Z.DE) stock?
The financial health rating of ZEALAND PHARMA A/S (22Z.DE) is 9 / 10.